Photocure ASA Logo

Photocure ASA

Develops and commercializes photodynamic technology for bladder cancer.

PHO | OL

Overview

Corporate Details

ISIN(s):
NO0010000045
LEI:
5967007LIEEXZXG8OW35
Country:
Norway
Address:
HOFFSVEIEN 4, 0275 OSLO

Description

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-08 08:00
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonst…
English 214.6 KB
2025-12-08 08:00
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonst…
English 9.0 KB
2025-11-19 08:00
New budget impact model study in 4 European countries concludes that BLC use of…
English 139.9 KB
2025-11-19 08:00
New budget impact model study in 4 European countries concludes that BLC use of…
English 9.5 KB
2025-10-31 08:25
Photocure ASA: Notification of primary insider transaction - Attachment: 202510…
English 74.7 KB
2025-10-31 08:24
Photocure ASA: Notification of primary insider transaction - Attachment: Releas…
English 107.9 KB
2025-10-31 08:24
Photocure ASA: Notification of primary insider transaction
English 1.4 KB
2025-10-29 07:00
Photocure ASA: Results for the third quarter of 2025 - Attachment: PHO_Q3_2025_…
English 1.6 MB
2025-10-29 07:00
Photocure ASA: Results for the third quarter of 2025 - Attachment: PHO_Q3_2025_…
English 997.3 KB
2025-10-29 07:00
Photocure ASA: Results for the third quarter of 2025 - Attachment: Release.pdf
English 183.0 KB
2025-10-29 07:00
Photocure ASA: Results for the third quarter of 2025
English 6.6 KB
2025-10-24 08:20
Photocure ASA: Invitation to presentation of third quarter 2025 financial resul…
English 2.4 KB
2025-10-15 17:08
Photocure and Intelligent Scopes Corporation partner on development of AI for b…
English 176.1 KB
2025-10-15 17:08
Photocure and Intelligent Scopes Corporation partner on development of AI for b…
English 11.6 KB
2025-09-22 08:23
Photocure ASA - Share option grant - Attachment: 20250922_PHO_Primary_insider_n…
English 110.6 KB

Automate Your Workflow. Get a real-time feed of all Photocure ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Photocure ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Photocure ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.